Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

Fig. 2

Percentage of patients with NIDL for FLIE overall combined score. Abbreviations: FLIE, Functional living Index-Emesis; NIDL, no impact on daily life; NEPA, a fixed combination of netupitant and palonosetron; DEX1, dexamethasone day 1; DEX3, dexamethasone day 1 to 3; DEX4, dexamethasone day 1 to 4

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us